| Barchart Demo Center |
$0.28
-0.26 (-48.15%)
as of 14:14 EST
as of 14:14 EST
| Last | 0.28 |
|---|---|
| Change | -0.26 (-48.15%) |
| Open | 0.25 |
| Prev. Close | 0.54 |
| Today's Range |
0.24
0.28
|
| 52wk Range |
0.24
3.72
|
| Volume | 29,244,628 |
| Avg Volume | 2,257,483 |
| Sector | All Sectors By Industry |
Perfomance Comparison
| Name | Today | 3-Month | 1-Year |
|---|---|---|---|
| BIOC |
 -48.15% |
 -65.25% |
-72.45% |
| DJIA |
-0.36% |
 +4.22% |
 +14.61% |
| S&P 500 |
-0.29% |
+6.07% |
+19.31% |
Key Statistics
| Annual EPS | -2.67 |
|---|---|
| Dividend Yield | 0.00% |
| P/E Ratio | N/A |
| Market Capitalization, $K | 11,810 |
| Weighted Alpha | -75.97 |
| Standard Deviation | -4.33 |
| Profit Margin | 3.63% |
| Beta | 1.71 |
Growth Rates
| YTD | -67.00% | |||
| 1-Year | -47.58% | |||
| 3-Year | -97.98% | |||
| 5-Year | -99.79% |
Opinion
| Sell | Hold | Buy |
Recent Headlines
Biocept Announces Pricing of $10.0 Million
PR Newswire via COMTEX - 09:15AM EST
Biocept, Inc. (NASDAQ: BIOC) ("Biocept" or the "Company"), a leading commercial provider of liquid biopsy solutions, today announced the pricing of an underwritten public offering of 24,600,000 shares of its common stock (or pre-f(full story)
BIOC: 0.28 (-0.26)
Biocept's Liquid Biopsy CTC Testing for Breast Cancer
PR Newswire via COMTEX - Tue Dec 03, 08:05AM EST
Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of molecular offerings designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, announces that cli(full story)
BIOC: 0.28 (-0.26)
Biocept Announces the Launch of its Liquid Biopsy Test
PR Newswire via COMTEX - Thu Nov 21, 08:05AM EST
Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, announces the comm(full story)
BIOC: 0.28 (-0.26)
Biocept Reports Third Quarter 2019 Financial Results
PR Newswire via COMTEX - Wed Nov 13, 04:05PM EST
Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of cancer patients, reports financial results for the(full story)
BIOC: 0.28 (-0.26)
Biocept Announces CE IVD Marks and Availability of its
PR Newswire via COMTEX - Thu Nov 07, 08:05AM EST
Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, announces CE (Conf(full story)
BIOC: 0.28 (-0.26)